Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 8:00 PM JST
Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K35/00 AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/181276COMPOSITION COMPRISING LACTOFERRIN AND PROBIOTIC BACTERIAL STRAINS FOR ORAL USE WITH ANTIVIRAL ACTION
WO 16.09.2021
Int.Class A61K 38/30
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
22Hormones
30Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
Appl.No PCT/IB2021/051959 Applicant SOFAR S.P.A. Inventor BIFFI, Andrea
The present invention relates to a composition comprising lactoferrin and, optionally, probiotic bacterial strains and/or N-acetylcysteine and/or hyaluronic acid for oral use as an antiviral agent, preferably for use in the treatment of viral infections of the respiratory system from a SARS-coronavirus (e.g. COVID-19).
2.WO/2021/181272BACTERIAL STRAINS AND COMPOSITIONS THEREOF FOR ORAL USE IN THE TREATMENT OF VIRAL INFECTIONS OF THE RESPIRATORY SYSTEM
WO 16.09.2021
Int.Class A61K 35/744
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
74Bacteria
741Probiotics
744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
Appl.No PCT/IB2021/051954 Applicant SOFAR S.P.A. Inventor BIFFI, Andrea
The present invention relates to bacterial strains and compositions thereof for use in the treatment of viral infections of the respiratory tract, preferably from coronavirus, such as for example a severe acute respiratory syndrome coronavirus (COVID-19), by stimulating and/or modulating cytokines and/or markers involved in the inflammatory processes of said viral infections of the respiratory tract.
3.WO/2021/216467A NANO-ENABLED VACCINATION APPROACH FOR CORONAVIRUS DISEASE (COVID-19) AND OTHER VIRAL DISEASES
WO 28.10.2021
Int.Class A61K 31/7088
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
Appl.No PCT/US2021/028004 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor NEL, Andre, E.
In various embodiments immunogenic nanoparticles are provided that are capable of raising an immune response directed against one or more viral proteins and/or protein fragments. In certain embodiments the immunogenic nanoparticles raise an immune response directed against a virus (e.g., SARS-CoV-2 (2019-nCoV), SARS-CoV-2, and MERS-CoV, and the like). In certain embodiments the immunogenic nanoparticles comprise a nanoparticle formed from one or more biocompatible polymer(s), one or more viral proteins or fragments thereof encapsulated within or attached to the biocompatible polymer(s) where the viral protein or fragment thereof comprises an antigen to which an immune response is to be induced by administration of the immunogenic nanoparticle to a mammal and where the immunogenic nanoparticle further comprises an adjuvant (e.g., a STING agonist).
4.20210353620METHODS AND USES OF PROTEIN DISULFIDE ISOMERASE INHIBITORY COMPOUNDS
US 18.11.2021
Int.Class A61K 31/496
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
Appl.No 17320069 Applicant The University of Vermont and State Agricultural College Inventor Vikas Anathy

Compositions and methods involving protein disulfide isomerase (PDI) inhibitors, such as protein disulfide isomerase A3 (PDIA3) inhibitory compounds, for human coronavirus, such as severe acute respiratory syndrome (SARS) virus (e.g., SARS-CoV-2), therapies are disclosed herein.

5.WO/2005/018535COMPOSITIONS AND METHODS FOR TREATMENT OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS)
WO 03.03.2005
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2004/015864 Applicant WYETH HOLDINGS CORPORATION Inventor SIBER, George, R.
Compositions and methods for treating Severe Acute Respiratory Syndrome (SARS) are disclosed herein. Inhibitors of SARS-associated inflammatory cytokines are provided herein for use in treating SARS, including SARS-associated coronavirus (SARS-CoV) infection. Inhibitors of TNF are disclosed herein, as is the use of said inhibitors for treating SARS, including SARS-CoV. Methods of identifying and screening for said inhibitors are also provided.
6.2009201478The severe acute respiratory syndrome coronavirus
AU 07.05.2009
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 2009201478 Applicant Novartis Vaccines and Diagnostics, Inc. Inventor
An outbreak of a virulent respiratory virus, now known as Severe Acute Respiratory Syndrome (SARS), was identified in Hong Kong, China and a growing number of countries around the world in 2003. The invention relates to nucleic acids and proteins from the SARS coronavirus. These nucleic acids and proteins can be used in the preparation and manufacture of vaccine formulations, diagnostic reagents, kits, etc. The invention also provides methods for treating SARS by administering small molecule antiviral compounds, as well as methods of identifying potent small molecules for the treatment of SARS.
7.WO/2021/217098TREATMENT OF VIRUS-INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME
WO 28.10.2021
Int.Class A61K 35/545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
48Reproductive organs
54Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
545Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
Appl.No PCT/US2021/028991 Applicant ABT HOLDING COMPANY Inventor TING, Anthony E.
The invention is directed to a method of treating viral-induced acute respiratory distress syndrome (ARDS) by administering to a subject with the virial induced ARDS multipotent adult progenitor cells (MAPCs), which are non-embryonic stem, non-germ cells that have a broad differentiation potential and extended replication capacity. The virus inducing the ARDS can be a Betacoronavirus, such as, severe acute respiratory syndrome (SARS), Corona Virus or Middle East Respiratory Syndrome (MERS), or severe acute respiratory syndrome Corona Virus 2 (SARS-CoV- 2).
8.WO/2021/202947METHOD FOR TREATING LUNG DISEASE WITH CELL-FREE AMNIOTIC FLUID
WO 07.10.2021
Int.Class A61K 35/50
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
48Reproductive organs
50Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
Appl.No PCT/US2021/025494 Applicant UNIVERSITY OF UTAH RESEARCH FOUNDATION Inventor TONNA, Joseph Edward
The present disclosure relates to a cell-free sterile filtered amniotic fluid that may be processed and/or supplemented to treat lung inflammation and/or fibrosis caused by lung disease.
9.WO/2021/234442NOSODES FOR THE PREVENTON, ALLEVIATION OF SYMPTOMS AND TREATMENT OF VIRAL INFECTIONS
WO 25.11.2021
Int.Class A61K 35/68
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
68Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
Appl.No PCT/IB2020/061176 Applicant SHAH, Rajesh Inventor SHAH, Rajesh
The present disclosure relates to the field of homeopathic formulations, particularly to a nosode composition for prevention, alleviation of symptoms and treatment of viral infections such as Coronavirus disease 2019 (Covid-19), Severe Acute Respiratory Syndrome (SARS), and Middle East Respiratory Syndrome (MERS). The composition is prepared from at least one biological material selected from the group consisting of live virus, viral glycoprotein, inactivated virus, viral envelope protein, viral nucleocapsid protein and virus irradiated infected cell lysate, wherein the biological material is obtained from clinical sample of virus infected patient or viral culture. The virus and/or the viral component for the preparation of nosodes is obtained from at least one of SARS CoV-2, SARS-CoV and MERS-CoV. The composition has a potency in the range of 1c to 1000c.The present disclosure further provides a method of preparing the nosode composition for prevention, alleviation and/or treatment of viral infections.
10.WO/2004/092360THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS
WO 28.10.2004
Int.Class A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
Appl.No PCT/US2004/011710 Applicant CHIRON CORPORATION Inventor RAPPUOLI, Rino
An outbreak of a virulent respiratory virus, now known as Severe Acute Respiratory Syndrome (SARS), was identified in Hong Kong, China and a growing number of countries around the world in 2003. The invention relates to nucleic acids and proteins from the SARS coronavirus. These nucleic acids and proteins can be used in the preparation and manufacture of vaccine formulations, diagnostic reagents, kits, etc. The invention also provides methods for treating SARS by administering small molecule antiviral compounds, as well as methods of identifying potent small molecules for the treatment of SARS.